A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.
Videos
Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.
An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.
Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.
Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.
Dr Yi-Bin Chen shares his thoughts on future directions and unmet needs in treatment of steroid-refractory GVHD.
Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.
Dr Yi-Bin Chen reviews treatment options for patients with steroid-refractory chronic GVHD.
Yi-Bin Chen, MD, discusses several approaches to the treatment of steroid-refractory acute GVHD, along with the immunologic pathways they target.
An expert in bone marrow transplantation outlines the main therapy used in the front-line setting to treat GVHD and then provides several definitions of what it means to be steroid-refractory.
Dr Yi-Bin Chen describes several prophylactic regimens commonly used to prevent GVHD following allogeneic hematopoietic stem cell transplant.
Yi-Bin Chen, MD, delineates between acute and chronic GVHD and provides the incidence and risk factors associated with these diseases.
Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.
Additional treatment options for low- and high-risk patients with MPNs are discussed.
Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.
A discussion of JAK inhibitors, risk models, quality of life, splenomegaly, and other issues in treating patients with MF.
Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.
Richard S. Finn, MD concludes the discussion by commenting on areas of unmet need in the care of HCC and emphasizes the potential impact of trials studying treatment combination and sequencing.
A thought leader in the management of hepatocellular carcinoma provides an overview of several clinical trials of combination therapy with lenvatinib including studies of real-world evidence and potential biomarkers.
An expert hematologist-oncologist considers the potential role of combination therapy with lenvatinib for patients with hepatocellular carcinoma.
A key opinion leader in liver cancer reviews the study design of the REFLECT trial of lenvatinib in patients with HCC and shares key insights into its safety and efficacy data.
Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.
An expert in hematology-oncology, Richard S. Finn, MD, provides an overview of hepatocellular carcinoma by discussing its prevalence, patient risk factors, and overall prognosis.
Eric Nadler, MD, MPP, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment studied in the IMpower133 trial in extensive-stage small cell lung cancer.
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the safety profile of ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.
Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.